| Literature DB >> 21931597 |
Lucas Binnenkade1, Jürgen Lassak, Kai M Thormann.
Abstract
The BarA/UvrY two-component system is well conserved in species of the γ-proteobacteria and regulates numerous processes predominantly by controlling the expression of a subset of noncoding small RNAs. In this study, we identified and characterized the BarA/UvrY two-component system in the gammaproteobacterium Shewanella oneidensis MR-1. Functional interaction of sensor kinase BarA and the cognate response regulator UvrY was indicated by in vitro phosphotransfer studies. The expression of two predicted small regulatory RNAs (sRNAs), CsrB1 and CsrB2, was dependent on UvrY. Transcriptomic analysis by microarrays revealed that UvrY is a global regulator and directly or indirectly affects transcript levels of more than 200 genes in S. oneidensis. Among these are genes encoding key enzymes of central carbon metabolism such as ackA, aceAB, and pflAB. As predicted of a signal transduction pathway that controls aspects of central metabolism, mutants lacking UvrY reach a significantly higher OD than the wild type during aerobic growth on N-acetylglucosamine (NAG) while under anaerobic conditions the mutant grew more slowly. A shorter lag phase occurred with lactate as carbon source. In contrast, significant growth phenotypes were absent in complex medium. Based on these studies we hypothesize that, in S. oneidensis MR-1, the global BarA/UvrY/Csr regulatory pathway is involved in central carbon metabolism processes.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21931597 PMCID: PMC3171408 DOI: 10.1371/journal.pone.0023440
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Domain organization of S. oneidensis MR-1 BarA (SO_3457; upper panel) and UvrY (SO_1860, lower panel).
White vertical bars mark the positions of transmembrane domains. HAMP, HAMP signal transduction domain; HisKa, histidine kinase dimerization domain; HATPase, histidine kinase ATPase domain; Rec, receiver domain; Hpt, histidine-containing phosphotransfer domain; HTH, helix-turn-helix DNA-binding motif.
Figure 2In vitro interaction of BarA and UvrY.
A) Autoradiographic analysis of BarA autophosphorylation. B) Autoradiographic analysis of phosphotransfer between BarA(181–929) and UvrY. Purified BarA181–929, UvrY, or UvrY(D54N) were added to the reactions as indicated and incubated for 60 s.
Figure 3Analysis of the predicted sRNAs CsrB1 and CsrB2.
A) Northern analysis of csrB1 and csrB2 transcripts. 15 µg total RNA isolated from S. oneidensis MR-1 LB cultures at late exponential growth phase were separated on a denaturing agarose gel. As a positive control, an unlabeled PCR product was used as s corresponding probe for csrB1 or csrB2 (DNA control). B) Genetic organization of the S. oneidensis MR-1 csrB locus. The predicted csrB1 and csrB2 genes are displayed in black, the surrounding genes in white. The csrB1 and csrB2 genes are separated by SO_1616, encoding a transposase. White vertical bars indicate the positions of predicted UvrY-binding boxes, black arrows putative transcripts. C) Putative UvrY-binding boxes upstream of csrB1 and csrB2.
Figure 4Analysis of csrB1 and csrB2 expression.
A) Growth phase-dependent csrB expression in complex medium. Total RNA was prepared from cells at the indicated time points and used to calculate the transcript copy number by q-RT-PCR. The error bars display the standard deviation. B) Decrease in expression of csrB1 and csrB2 in uvrY and barA mutants. Total RNA was prepared from cells of the appropriate mutant strain at late exponential phase, and the mRNA levels of csrB1 and csrB2 were quantified by q-RT-PCR. The error bars display the standard deviation.
Figure 5Aerobic and anaerobic growth of S. oneidensis wild type and ΔuvrY mutant in different media.
The upper panel (A–C) displays growth under aerobic conditions, the lower panel (D–F) under anaerobic conditions. The corresponding electron donors and acceptors are indicated. Growth of the wild type is displayed in black, that of ΔuvrY in grey. In order to better highlight the differences in growth behavior, growth was plotted at a linear scale. The error bars display the standard deviation. NAG, N-acetylglucosamine.
Figure 6Expression levels of csrB1 and csrB2 system during growth with different carbon sources.
Total RNA was prepared from cells growing in different media at early and late exponential phase as indicated below. The total RNA was then used to calculate the number of csrB1 and csrB2 transcripts by q-RT-PCR. NAG, N-acetylglucosamine.
Strains and plasmids used in this study.
| Strain or plasmid | Relevant genotype or description | reference |
| Bacterial strains | ||
|
| ||
|
|
|
|
|
| Donor strain for conjugation with | W. Metcalf, University of Illinois, Urbana-Champaign |
|
| F_ | Euromedex, France |
|
| ||
| MR-1 | Wild type |
|
| ΔSO_3457 | in-frame deletion of SO_3457 ( | this study |
| ΔSO_1860 | in-frame deletion of SO_1860 ( | this study |
| ΔSO_3457 ΔSO_1860 | in-frame deletion of SO_3457 ( | this study |
| ΔcrsB1ΔcsrB2 | in-frame deletion of the gene region between SO_1617 and SO_1619 encoding CsrB1 and CsrB2 separated by SO_1616 encoding a transposase | |
| S 198 | MR-1, tagged with eGfp in a mini-Tn |
|
| ΔSO_1860 gfp | ΔSO_1860, tagged with eGfp in a mini-Tn | this study |
| Plasmids | ||
| Construction of in-frame deletions | ||
| pNPTS138-R6KT |
|
|
| pNPTS138-R6KT-ΔSO_3457 | SO_3457 ( | this study |
| pNPTS138-R6KT-ΔSO_1860 | SO_1860 ( | this study |
| pTNS2 | ori-R6K; encodes the TnsABC+D specific transposition pathway, Apr |
|
| pUC18-R6KT-miniTn7T-egfp | MiniTn |
|
| Overexpression of SO_3457 ( | ||
| pBAD-HisA | Over-expression vector; L-arabinose promoter; N-terminal 6xhistidine fusion tag; Ampr | Invitrogen, Frankfurt, Germany |
| pGEX-4T1 | Over-expression vector; lactose promoter; N-terminal GST fusion tag; Ampr | GE Healthcare, München, Germany |
| pBAD-HisA-SO_3457 | SO_3457 ( | this study |
| pGEX-4T1-SO_1860 | SO_1860 ( | this study |
| pGEX-4T1-SO_1860_D54N | SO_1860 ( | this study |
Ampr, ampicillin resistance; Cmr, chloramphenicol resistance; Kmr, kanamycin resistance.